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 Abstract. WWOX is a candidate tumour suppressor gene that
exhibits LOH or homozygous deletion in several tumour types.
As well as the predominant full-length transcript (variant 1)
there also exist alternatively spliced transcripts found
previously only in malignant tissue. It has been suggested
that proteins encoded by these variants may interfere with
normal WWOX function in a dominant negative fashion. The
most prevalent alternate transcript demonstrated in ovarian
cancer is variant 4, which lacks exons 6-8. Here, we report
the first comparison of the mRNA expression of WWOX
variants 1 and 4 in human ovarian tumours and normal ovaries,
and correlate expression with clinical data. We demonstrate
significantly lower WWOX variant 1 expression in tumours
than in normal ovaries. This reduction was not associated
with any specific clinical subgroup. Variant 4 was expressed
at low levels, and significantly associated with high grade
and advanced stage ovarian cancer. Furthermore, tumours
co-expressing variant 4 and relatively high levels of variant 1
showed significantly worse survival than tumours expressing
variant 1 alone. However, variant 4 was also frequently
identified in non-malignant ovarian tissue. These results support
the role of WWOX variant 1 as a suppressor of ovarian tumouri-
genesis, but the role of variant 4 remains speculative.
Introduction
Loss of heterozygosity (LOH) of chromosome 16q has been
described in ovarian, breast, prostate and other cancers (1-6).
Later studies identified 16q23-24 as a region of particularly
high allelic loss (7-10), suggesting that there was a tumour
suppressor gene in this region. Recently the WWOX gene was
mapped to 16q23.3-24.1 (11). The 2.2 kb WWOX transcript is
encoded by 9 exons and spans a region of >1 Mb. This region
encompasses FRA16D (12,13), the second most frequently
expressed common fragile site in the human genome.
Functional evidence exists for the role of WWOX as a
tumour suppressor. Overexpression of the gene in breast
cancer cell lines with low baseline WWOX expression resulted
in strong inhibition of anchorage-independent growth in soft
agar and dramatic suppression of tumourigenicity in vivo (14).
Studies with the murine homologue, WOX1, suggest that it
interacts with p53 and plays a role in apoptosis (15). However,
examples of mutations in the human WWOX gene are sparse
(11,16). One somatic leucine to proline missense mutation, two
residues from the putative active site, was identified in an
esophageal cancer that also showed LOH, suggesting possible
inactivation of both alleles (17). Homozygous deletions
disrupting both alleles of the WWOX gene have been reported
in a variety of cancer cell lines and in human primary tumour
material (16), and high frequency of allelic loss involving
WWOX has been shown in ovarian, esophageal (17) and non-
small cell lung cancers (18).
In light of the paucity of mutations, we chose to investigate
other mechanisms of WWOX dysregulation, such as reduced
expression or the production of aberrant isoforms, that may
play a role in cancer. Alternative mRNA variants of WWOX
with unique 3'-terminal exons have been described (19), and
aberrant variants of WWOX have been identified in cancer
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cell lines and tumour tissue (14,16-18,20,21). In ovarian
tumours the predominant aberrant transcript is the ∆6-8
(variant 4) transcript that skips exons 6-8 (16). These variants
lack the sequence encoding the enzymatic oxidoreductase
domain, but retain the sequence encoding the protein binding
WW-domains, leading some investigators to postulate that they
may function in a dominant negative fashion by sequestering
WWOX-binding proteins. During the preparation of this
manuscript, two studies have reported the use of antibodies
that recognise WWOX short-form proteins (21,22). Watanabe
et al (22) could only detect alternate transcript expression
if the proteasome was blocked. In contrast, Ishii et al (21)
did identify the presence of WWOX short form proteins in
haematopoietic malignancies, although no indication of the
specificity of the antibody was given. In this report, we
demonstrate that the sensitivity of a WWOX-specific anti-
body is orders of magnitude below that required to detect the
WWOX short-form proteins in solid tumours. We therefore
used quantitative RT-PCR to investigate the mRNA expression
levels of full length WWOX (variant 1) and the predominant
alternate transcript ∆6-8 (variant 4) in malignant and normal
ovarian tissues. We further determined whether the expression
of these variants correlated with clinico-pathological factors
or patient survival. We report that the expression of WWOX
variant 1 in ovarian tumours is significantly reduced as
compared with normal ovary tissue, supporting a tumour
suppressor role for WWOX. However, the clinical significance
of the alternate variant 4 transcript remains uncertain.
Materials and methods
PEO1 transfections. The WWOX variant 1 coding region
was inserted into the pEF6/V5-His TOPO-cloning vector
(Invitrogen, Paisley, UK) and this construct was stably trans-
fected into a hygromycin-tagged derivative of the PEO1
ovarian cancer cell line (PEO1hyg1.6) using Effectene Reagent
(Qiagen, Crawley, UK).
Western blot analysis. Cells grown in monolayer culture were
harvested and lysed with lysis buffer supplemented with 1X
Complete protease inhibitors (Roche, UK) and 0.5 mM phenyl-
methylsulfonyl fluoride. Following incubation on ice for
15 min, the lysate was centrifuged at 13,000 rpm for 5 min, and
the postnuclear supernatant was harvested and sampled for
quantitation of protein concentration, using the BioRad protein
reagent. Forty micrograms of the lysate were then mixed with
SDS-PAGE sample buffer, boiled for 5 min, and subjected
to electrophoresis in 10% SDS-PAGE gels under reducing
conditions. The separated proteins were electrophoretically
transferred to Trans-Blot transfer membrane (BioRad, UK).
Blots were incubated with primary anti-WWOX (a polyclonal
antibody, raised in rabbit using as antigen a fusion protein of
GST bound to the WW-domains of WWOX) or anti-GAPDH
(Abcam, Cambridge UK) antibodies overnight at 4˚C. Immuno-
complexes were visualized with the BM chemiluminescence
detection kit (Roche) using horseradish peroxidase-conjugated
secondary antibodies. Quantitative values for WWOX and
GAPDH proteins were obtained by densitometric analysis
using a gel scanner (UVP Life Sciences, Cambridge, UK)
and analyzed by Labworks gel analysis software (UVP
Life Sciences, Cambridge, UK). This provided integrated
absorbance values.
Preparing RNA from transfected PEO1 cell lines. DNase I-
treated total RNA from the transfected PEO1 cell lines was
prepared using the Absolutely RNA RT-PCR Miniprep Kit
(Stratagene, CA). First strand cDNA was prepared from 2 µg
of DNase-treated RNA using a first strand cDNA synthesis
kit (Roche).
Preparing RNA from human tissues. Primary ovarian tumour
material and non-malignant tissues were obtained from patients
undergoing gynaecological surgery in Lothian University
Hospitals NHS Trust, Scotland, UK. Institutional ethical
approval was granted for this work by the Lothian University
National Health Service Trust Medicine/Clinical Oncology
Research Ethics Subcommittee. Tissue samples were excised,
transferred on ice for section then transferred into liquid
nitrogen. Eighty-three consecutive tumour samples were
taken from this bank for analysis. Twelve were excluded
before analysis: 3 on histological grounds (primary peritoneal,
cystadenoma, pseudomyxoma peritonei); 4 samples were not
obtained at the time of primary surgery; extraction of RNA
was unsatisfactory in 2 cases; 2 patients had concurrent
malignancies at the time of diagnosis and 1 patient had no
available clinical information. Tumour characteristics of
the remaining 71 tumours are described in Table I.
Thirteen non-malignant tissue samples were taken from our
tissue bank for analysis. These patients underwent bilateral
oophorectomies for suspected malignancy but were found to
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Table I. Grade, stage and histology of 71 epithelial ovarian
tumours.
–––––––––––––––––––––––––––––––––––––––––––––––––
Tumour characteristic No. of patients
–––––––––––––––––––––––––––––––––––––––––––––––––
Grade
1 3
2 16
3 49
Unknown 3
Stage
I 11
II 6
III 41
IV 10
Unknown 3
Histology
Serous papillary 36
Endometrioid 13
Clear cell 10
Mucinous 6
Mixed serous papillary/ 4
Endometrioid
Unknown 2
–––––––––––––––––––––––––––––––––––––––––––––––––
have various benign histologies such as serous cystadenoma,
fibrothecoma, ovarian fibroma, endometriosis and salpingitis.
On each occasion, the apparently normal contralateral ovary
was used for our analysis. DNase I-treated total RNA and
first strand cDNA were prepared as for the transfected PEO1
cell lines.
Non-quantitative RT-PCR. Non-quantitative RT-PCR was per-
formed to analyse WWOX expression in normal ovary and
ovarian tumour samples. Reactions (25 µl) contained 2 µl
first strand cDNA, 200 nM dNTPs, 1X PCR buffer, 1 U Taq
Gold (Applied Biosystems, UK) or Pic Taq (Cancer Research
UK), MgCl2 and 0.2 µM (Taq Gold) or 0.8 µM (Pic Taq) of
each primer (magnesium concentrations, primer sequences
and cycling conditions in Table II). Initiation steps of 95˚C
for 12 min (Taq Gold) and 94˚C for 3 min (Pic Taq) were
used pre-cycling.
Exon-specific genomic PCR. Genomic DNA from the two
tumours that did not express WWOX variant 1 on the basis of
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Table II. PCR primers and conditions.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
PCR Primers Sequences (5'-3') For/Rev [Mg2+]/ Cycling conditions
Taqa
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Non- 8F2+Z2 ACTATTGGGCGATGCTGGCT 2.5 mM 95˚C 30 sec; 65˚C 30 sec;
quantitative (exons 8 and 9) CGTTCTTGGATCAGCCTCTC Gold 72˚C 45 sec; 40 cycles TDb
RT-PCR 7F2+8R2 CACCAAAGATGGCCTGGA 2.0 mM 94˚C 30 sec; 65˚C 30 sec;
(exons 7 and 8) TGGACCTGTTATAAGCCAGCATCG Pic 72˚C 30 sec; 30 cycles TD
Ex4/4+Z2 TTTCACTGGCAAAGTGGTTG 2.5 mM 95˚C 30 sec; 57˚C 30 sec;
(exons 4-9) CGTTCTTGGATCAGCCTCTC Gold 72˚C 75 sec; 35 cycles
Ex1/1+CodR GAGTTCCTGAGCGAGTGGAC 2.5 mM 95˚C 30 sec; 57˚C 30 sec;
(5'UTR-3'UTR) ACTTTCAAACAGGCCACCAC Gold 72˚C 75 sec; 35 cycles
Exon-specific Exon 1F+R GGAGACTGGATTTCAGCTTC 1.6 mM 94˚C 30 sec; 65˚C 30 sec;
PCR on (exon 1) CCCTGGACCCTTTTCCCT Pic 72˚C 30 sec; 30 cycles TD
genomic DNA Exon 2F+R GTCCTCTTTCTCCTTCTTCC 1.6 mM 94˚C 30 sec; 55˚C 30 sec;
(exon 2) CAATAACCTGTCACCTCTCT Pic 72˚C 30 sec; 35 cycles
Exon 3F+R GTCTTTACTTCTCCCTGGCACC 1.6 mM 94˚C 30 sec; 56˚C 30 sec;
(exon 3) GCGGGGAAAATAGAAGAATA Pic 72˚C 30 sec; 35 cycles
Exon 4F+R CTTTCTCTTTTGGGCAGC 1.6 mM 94˚C 30 sec; 58˚C 30 sec;
(exon 4) GCAGTCCCAAAGATAAATAAC Pic 72˚C 30 sec; 35 cycles
Exon 5F+R AGGACTCTACCCCACAAC 2.0 mM 94˚C 30 sec; 68˚C 30 sec;
(exon 5) ACACACTCCACTGAAATC Pic 72˚C 30 sec; 40 cycles TD
Exon 6F+R ATTAAACAGGGGAATTCCGAC 1.6 mM 94˚C 30 sec; 63˚C 30 sec;
(exon 6) TCTCCCAATTGTGTTCATCTG Pic 72˚C 30 sec; 30 cycles TD
Exon 6aF+R TAGGAGGTGTTGGAAGAAGG 1.6 mM 94˚C 30 sec; 56˚C 30 sec;
(exon 6a) CACCTGAAGAGTCGTAAAGC Pic 72˚C 30 sec; 35 cycles
Exon 7F+R2 ACATCCATGGATCCCGAAG 1.6 mM 94˚C 30 sec; 55˚C 30 sec;
(exon 7) TGATTCACTTGAAAGGTGGTCT Pic 72˚C 30 sec; 40 cycles
Exon 7F2+R CACCAAAGATGGCCTGGA 1.6 mM 94˚C 30 sec; 65˚C 30 sec;
(exon 7) TGGTATGAGAAAGGGGATAAGTG Pic 72˚C 30 sec; 30 cycles TD
Exon 8F+R TGCACCCAGCATTCCTTAGATTTCC 1.6 mM 94˚C 30 sec; 65˚C 30 sec;
(exon 8) ACCAGACTCATGCCCGCAAG Pic 72˚C 30 sec; 30 cycles TD
Exon 9F+R GACGCCATCTCATCACTCC 1.6 mM 94˚C 30 sec; 65˚C 30 sec;
(exon 9) TTTACTTTCAAACGGCCACC Pic 72˚C 30 sec; 40 cycles TD
Quantitative ß-actin F+R CTACGTCGCCCTGGACTTCGAGC SYBR 95˚C 15 sec; 57˚C 60 sec; 85˚C
real-time GATGGAGCCGCCGATCCACACGG 15 sec (aquire); 40 cycles
RT-PCR 8F2+Z2 ACTATTGGGCGATGCTGGCT SYBR 95˚C 30 sec; 67˚C 30 sec; 72˚C 45 sec;
(exons 8 and 9) CGTTCTTGGATCAGCCTCTC 85˚C 15 sec (aquire); 45 cycles TD
∆6-8 F+R GGTTGTGGTCACTGGAGCTAA SYBR 95˚C 15 sec; 67˚C 60 sec; 78˚C 15 sec
(exons 4 and 5/9 junct) CAGCTCCCTGTTGCCATTC (aquire); 45 cycles TD
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Primer sequences, magnesium concentrations, type of Taq DNA polymerase and cycling conditions used for non-quantitative RT-PCRs,
exon-specific PCRs on genomic DNA and quantitative real time RT-PCR. aGold, Taq Gold; Pic, Pic Taq; SYBR, SYBR Green PCR
Mastermix (containing MgCl2). bTD, annealing temperature decreased by 1˚C per PCR cycle for first 10 cycles.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
non-quantitative RT-PCR was screened for possible homo-
zygous deletions by PCR amplification of individual WWOX
exons. Reaction conditions as above and primers as in
Table II.
Quantitative real-time RT-PCR. Quantitation of mRNA levels
for ß-actin, WWOX variant 1 (primers 8F2 and Z2) and WWOX
variant 4 (primers ∆6-8F and ∆6-8R) was carried out in
quadruplicate 20 µl reactions containing 1X SYBR Mastermix
(Applied Biosystems), either 0.2 µl (ß-actin and WWOX
variant 1) or 1 µl (WWOX variant 4) first strand cDNA, and
the relevant primer pair (listed in Table II). Final concentration
of ß-actin primers was 200 nM each, of variant 1 specific
primers was 400 nM each, and of variant 4-specific primers
was 200 nM (forward) and 50 nM (reverse). Reactions were
run on the Rotorgene 2000 real-time PCR machine (Corbett
Research, Australia), and fluorescence was detected using the
FAM channel (source 470 nm; detector 510 nm). The PCR
conditions for each primer pair are given in Table II, and all
included a 15 min Taq activation step at 95˚C before cycling,
and a 4 min step at 72˚C and a melt curve post-cycling.
Specificity for variant 4 was obtained by designing the reverse
primer to anneal across the exon 5-9 splice junction that is
unique to the variant 4 transcript. Previous studies have used
a similar reverse primer and found no cross-amplification
from variant 1 (full length) cDNA (14). To ensure that our
variant 4-specific primers did not misprime from variant 1
transcript, a mispriming control was included in all PCRs.
This control was derived by transfecting a variant 1-over-
expressing plasmid into PEO1 cells, which express no
endogenous variant 1 or variant 4. Variant 1 expression in
this control line was in excess of that in the tumour samples
(data not shown). A negative result in this control sample
would thus indicate that the variant 4-specific PCR primers
cannot misprime from the levels of variant 1 present in the
tumours.
A standard curve was included in each run in triplicate
and was prepared from four serial dilutions of cell line cDNA.
For a standard curve to be accepted the best fit line had to
have an R-value >0.99. Expression levels were extrapolated
from the standard curve and normalised relative to ß-actin
expression for each sample. Selected products were run on a
2% agarose gel to confirm band size. To confirm sequence
identity, selected samples were purified by treatment with
Exonuclease I and Shrimp Alkaline Phosphatase (Amersham
Pharmacia, UK), sequenced with ABI Prism Big Dye and
precipitated, according to manufacturer's instructions
(Applied Biosystems).
Statistical analysis. Analyses for clinicopathological
associations were conducted using Fisher's exact test, Mann-
Whitney test and linear regression. These analyses were
performed using SPSS Version 10 (SPSS Inc., USA) and the
Analyse-it plug-in (Analyse-it Software Ltd., UK) for Micro-
soft Excel. Univariate analysis was performed comparing
clinicopathological factors and WWOX variant expression to
survival. All parameters found to be significant at the univariate
level were included in the multivariate Cox regression analysis
(forward stepwise likelihood ratio method; entry probability
0.05; removal probability 0.1).
Results
Low level WWOX expression is detectable by real-time RT-PCR
but not by immunoblotting. To assess the sensitivity of real-
time quantitative RT-PCR and immunoblotting for measuring
WWOX expression we used the PEO1hyg1.6 cell line.
PEO1hyg1.6 cells are homozygously deleted for exons 4-8 of
the WWOX gene, and thus express no full-length WWOX. We
transfected these cells with a construct containing the WWOX
variant 1 coding region, and quantified WWOX variant 1
mRNA and protein expression in the resultant transfectants
by real-time RT-PCR and Western blot, respectively. Real-
time RT-PCR detected variant 1 expression in 6 out of 6 of
the transfectants but not in the parent line (Fig. 1A). No WWOX
variant 1 expression was detected in 3 vector-transfected
controls (data not shown). Western blot analysis detected a
single band corresponding to isoform 1 expression in 4 out of
the 6 sense transfectants (Fig. 1B), and there was a strong
linear correlation between WWOX mRNA and protein levels
in this transfected cell line system (R2=0.995; Fig. 1C). The
two transfectants in which protein was not detected were the
lowest expressers of WWOX variant 1 mRNA by real-time
RT-PCR (amplifying after 20-22 cycles when using 0.2 µl of
first strand cDNA in the RT-PCR). This suggests that the
sensitivity of the WWOX immunoblotting is less than the
real-time RT-PCR. Due to its greater sensitivity we therefore
used quantitative RT-PCR to investigate the WWOX expression
profile in ovarian cancer.
Full-length WWOX variant 1 is absent in two ovarian tumours.
Non-quantitative RT-PCR using primers amplifying between
exons 8 and 9 (primers 8F2 and Z2) revealed a product for all
of the normal ovarian samples and 69 out of 71 tumour
samples. The lack of full-length WWOX expression in the
remaining two tumours was confirmed using two further
primer sets amplifying between exons 7 and 8 (primers 7F2
and 8R2) and exons 4 and 9 (primers Ex4/4 and Z2). RT-PCR
amplification across the whole open reading frame for these
two tumours (using primers Ex1/1 and CodR) revealed a
truncated product of ~950 bp for one of the tumours and no
product for the other tumour. We were unable to successfully
clone the 950 bp product, and its size does not appear to match
any known splice variants. Exon-specific PCR from genomic
DNA revealed that all the exons were present in both cases,
ruling out the possibility of homozygous deletion.
Full-length WWOX variant 1 expression is reduced in ovarian
tumours as compared to normal ovarian tissues. The relative
WWOX variant 1 expression (WWOX/ß-ACTIN), as determined
by quantitative real-time RT-PCR, varied from 9.3 to 61.6
(median 22.9) in the 69 normal ovarian tissues and from 0 to
58.7 (median 9.57) in the ovarian tumours. Neither group of
samples had a normal distribution of variant 1 expression
(Fig. 2) but the median WWOX variant 1 expression was
highly significantly reduced in the ovarian tumours compared
to the normal tissues (p<0.0001; Mann-Whitney test). The
level of WWOX variant 1 expression was not associated with
any particular clinicopathological factor, but was decreased
across all the tumour subtypes, suggesting that reduced
WWOX variant 1 expression may be an early event in ovarian
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tumourigenesis. There was no significant difference in survival
between high (actin-corrected level >10) and low (actin-
corrected level <10) WWOX variant 1 expressers (Fig. 3A).
WWOX variant 4 expression in ovarian tumours is associated
with stage, grade and poorer survival. To determine the
expression of WWOX variant 4 in the 69 ovarian tumours, we
performed non-quantitative RT-PCR on first strand cDNA
using primers amplifying between exons 4 and 9 (primers
Ex4/4 and Z2). This primer pair can amplify from both
variant 1 and variant 4, producing products of 860 and 321 bp,
respectively. The 321 bp variant 4 product lacking the exons 6-
8 sequence was present in >50% of the tumour samples. In
addition, two other PCR products, with sizes intermediate
between the variant 1 and variant 4 products, were identified
in a total of 12 out of 71 tumours (17%). Based on size criteria,
these were assumed to be transcripts with deletions of exons 7
and 8 (~410 bp) and of exon 7 alone (~675 bp).
Thus, as was previously reported by us, WWOX variant 4
appears to be the most common alternate splice variant in
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Figure 1. (A), Graph showing the expression of WWOX variant 1 mRNA in transfected cell lines. Relative WWOX variant 1 expression (calculated as the ratio
of WWOX to ß-ACTIN mRNA levels) was measured by quantitative real-time RT-PCR using the Rotorgene 2000. PEO1hyg1.6 cells were the parent cell line
used for transfection, and express no variant 1. The sense transfectants (H6, H7, H8, H9, H10 and H12) were generated by transfection of PEOhyg1.6 cells
with a construct containing the WWOX variant 1 coding region, and express varying levels of variant 1 mRNA. (B), Graph showing the expression of WWOX
isoform 1 protein in transfected cell lines. Protein lysate (40 µg) from each cell line was separated by electrophoresis on 10% SDS-PAGE gels, and was
transferred to Trans-Blot membrane. WWOX isoform 1 was detected using a rabbit anti-WWOX antibody. GAPDH was detected using an anti-GAPDH
antibody and was used as a loading control. No WWOX variant 1 protein was detectable in the parent line PEO1hyg1.6 or the sense transfectants H9 and H12.
Variable levels of variant 1 expression were detected in the H6, H7, H8 and H10 transfectants. (C), Graph comparing WWOX variant 1 mRNA and protein
levels in the transfected cell lines. Relative WWOX variant 1 mRNA expression (calculated as the ratio of WWOX to ß-ACTIN mRNA levels) was measured
by quantitative real-time RT-PCR using the Rotorgene 2000. Relative WWOX isoform 1 protein expression (calculated as the ratio of WWOX to GAPDH
protein levels) was measured by densitometry from immunoblots. A strong linear correlation between variant 1 mRNA and protein levels (R=0.9953) is
shown.
A C
B
Figure 2. Graph showing WWOX variant 1 mRNA expression in 71 ovarian
tumours (black bars) and 13 normal ovarian tissues (white bars). Relative
WWOX variant 1 expression (calculated as the ratio of WWOX to ß-ACTIN
mRNA levels) was measured by quantitative real-time RT-PCR using the
Rotorgene 2000. The median WWOX variant 1 expression is significantly
lower in the tumours than in the normals (p<0.0001, Mann-Whitney test).
ovarian tumours. However, to eliminate any possible inter-
ference in the PCR due to the competitive amplification of
multiple variants, we developed a highly specific real-time
RT-PCR for the detection of variant 4 using the Rotorgene
2000 (see Materials and methods). We utilised a primer pair
(∆6-8F and ∆6-8R) of which the reverse primer was designed
to anneal to the exons 5-9 splice boundary that is unique to
the variant 4 transcript. We routinely used a mispriming control
to ensure that this variant 4-specific RT-PCR did not generate
false positives by mispriming from variant 1 transcript (see
Materials and methods). Expression of WWOX variant 4 was
detected in 45 out of 71 (63%) ovarian tumour samples and
was generally very low, amplifying after 32-39 cycles of
PCR when using 1 µl of first strand cDNA per reaction. By
comparison, variant 1 amplified significantly after 19-32 cycles,
when using 0.2 µl of cDNA per reaction. The level of variant 4
expression in the tumours is lower than the standard curve
generated for this RT-PCR, making quantitation of variant 4
levels unreliable. Nonetheless, this study accurately and
sensitively detects the presence of variant 4 transcript in the
tumours, and this expression pattern was analysed with
respect to clinicopathological factors. There was a significant
association between the presence of the variant 4 transcript
and high grade ovarian cancer (p=0.006; Fisher's exact test;
Table IIIA). The presence of the variant 4 transcript was
also significantly associated with advanced stage disease
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Figure 3. Patient survival according to WWOX expression. Relative WWOX
variant 1 and variant 4 expression (calculated as the ratio of WWOX to ß-
ACTIN mRNA levels) was measured by quantitative real-time RT-PCR
using the Rotorgene 2000. (A), Patients were divided into two groups with
relative variant 1 expression levels >10 and <10. No significant difference in
survival between the two groups was apparent. (B), Patients were divided
into two groups, variant 4 expressers and variant 4 non-expressers. Patients
expressing variant 4 showed a trend towards poorer survival, but this did not
reach significance. (C), 33 patients whose tumours expressed high relative
WWOX variant 1 levels (>10) were divided into two groups, variant 4
expressers and variant 4 non-expressers. Patients with high levels of WWOX
variant 1 who co-expressed variant 4 showed a significantly poorer survival
than those with no variant 4 (p=0.048).
Table III. A, Contingency table showing WWOX variant 4
expression according to ovarian tumour grade (for 66 of 69
patients for whom tumour grade information was available).
–––––––––––––––––––––––––––––––––––––––––––––––––
Tumour grade Total
–––––––––––
1/2 3
–––––––––––––––––––––––––––––––––––––––––––––––––
No WWOX variant 4 11 12 23
expression
WWOX variant 4 6 37 43
expression
Total 17 49 66
–––––––––––––––––––––––––––––––––––––––––––––––––
P=0.006, Fisher's exact test.
–––––––––––––––––––––––––––––––––––––––––––––––––
B, Contingency table showing WWOX variant 4 expression
according to ovarian tumour stage (for 66 of 69 patients for
whom tumour stage information was available).
–––––––––––––––––––––––––––––––––––––––––––––––––
Tumour stage Total
–––––––––––––
I/II III/IV
–––––––––––––––––––––––––––––––––––––––––––––––––
No WWOX variant 4 10 14 24
expression
WWOX variant 4 5 37 42
expression
Total 15 51 66
–––––––––––––––––––––––––––––––––––––––––––––––––
P=0.006, Fisher's exact test.
–––––––––––––––––––––––––––––––––––––––––––––––––
(p=0.012; Fisher's exact test; Table IIIB). There was no
correlation between expression of variant 4 and histology of
ovarian tumour.
Variant 4 expression in the tumours was also compared
with patient survival by Kaplan-Meier analysis. There was
a trend towards worse survival in those patients whose tumours
expressed WWOX variant 4 but this did not reach significance
(p=0.057; Fig. 3B). However, in the patients expressing high
levels of variant 1 (actin-corrected level >10), those that co-
expressed variant 4 had significantly worse survival compared
with those that did not (p=0.048; Fig. 3C). In contrast,
expression of variant 4 did not significantly alter the survival
in patients expressing low levels of variant 1 (data not shown).
Analysis of variant 4 in a multivariate model demonstrated that
expression of this variant was not an independent prognostic
variable.
WWOX variant 4 is expressed in normal ovary tissue. We
repeated the variant 4-specific real-time RT-PCR (primers
∆6-8F and ∆6-8R) on cDNA from the normal ovary samples.
WWOX variant 4 expression was surprisingly detected in 9
out of 13 (69%) normal ovarian tissue samples, a frequency
similar to that detected in the tumours. The relative WWOX
variant 4 expression (WWOX/ß-ACTIN) was low and appeared
similar in the normal ovarian tissues (from 0 to 0.33) and in
the ovarian tumours (from 0 to 3.65), although quantitation of
such low expression is unreliable. Expression of variant 4 is
thus not limited to malignant tissues.
Discussion
The WWOX gene was identified from a study of human breast
cancer, and has subsequently been suggested as a tumour
suppressor gene for a number of different tumour types. This
is supported by the observations that WWOX is capable of
tumour suppression in vivo in a breast cancer cell line model,
and its apparent role in apoptosis in murine fibroblast studies.
However, inactivating mutation or epigenetic silencing of
WWOX in primary tumours is rare, which questions the clinical
significance of this gene. Because of this contradiction
between the strong functional evidence of WWOX tumour
suppression and rare gene inactivation in tumours, we decided
to investigate potential alternative mechanisms of WWOX
dysfunction in ovarian cancer - namely decreased gene
expression and production of alternate WWOX variant splice-
forms.
Until very recently, the available antibodies directed against
WWOX protein only recognised the full-length variant 1
protein, not any of the shorter forms. Two groups have now
generated antibodies that detect WWOX short-form proteins.
Watanabe et al (22) could only detect expression of short-
form proteins if the proteasome was blocked. They inter-
preted this as meaning that these isoforms were targeted for
destruction and were not biologically active. While this may
be true, we show here that the sensitivity of the real-time
RT-PCR assay is superior to immunoblotting as evidenced
by PEO1 WWOX transfectants that express low level WWOX
variant 1 mRNA but no detectable protein. We also show that
expression of the alternate transcripts is generally orders of
magnitude lower than that of variant 1. Thus it may be that
the short-form proteins are expressed at levels below the
sensitivity of the available antibodies, and that blocking the
proteasome could result in the alternative isoforms rising to a
level that is detectable by immunoblotting.
We demonstrated a tight linear correlation between
WWOX mRNA and protein levels in transfected cells. Based
on this, and the greater sensitivity of RT-PCR, we chose to
use quantitative real-time RT-PCR to investigate the expression
profile of WWOX variant 1 and variant 4 (the predominant
alternate variant in ovarian tumours) in a panel of normal ovary
tissues and ovarian tumours. We have demonstrated that
WWOX variant 1 mRNA expression is significantly reduced
in human ovarian tumours compared to normal ovarian tissues,
supporting its role as a tumour suppressor gene. In contrast to
the rarity of point mutation in the WWOX gene, we found
decreased expression of WWOX variant 1 to be highly frequent
in ovarian cancer. Tumours in our study showed 87% (60/69)
variant 1 expression levels lower than the median expression
level of the normal ovaries, and 49% (34/69) of the tumours
exhibited less variant 1 expression than the lowest expressing
normal ovary sample. Thus reduced WWOX variant 1
expression was apparent in the majority of the ovarian tumours.
In addition, 2/71 tumours expressed no full length variant 1.
This frequency is consistent with previous reports describing
the absence of variant 1 in 1/36 oesophageal cancers (17),
in 2/27 non-small cell lung cancers (18) and in 1/20 breast
cancers (20). The latter example, like our two cases,
demonstrated no evidence of exonic homozygous deletion.
We have also demonstrated the expression of the variant 4
transcript in 63% of our panel of human ovarian tumours.
This compares to a frequency of only 5.5% in oesophageal
squamous cell carcinoma (17) and 11.1% in non-small cell
lung carcinoma (18), although a further 14.8% of these lung
tumours showed other alternate transcripts. It is unlikely that
this discrepancy in variant 4 expression frequency is related
to the different methods of detection, since we also detected a
high frequency of variant 4 expression in ovarian tumours
(50%) using a competitive, non-quantitative PCR similar to
that used in the earlier studies. The expression of variant 4
mRNA was significantly associated with high tumour grade
and advanced stage ovarian carcinoma. There was a trend
towards adverse survival in patients who expressed this variant
and significantly worse survival in those patients with robust
variant 1 expression who co-expressed variant 4.
There are several possible explanations for the association
of WWOX variant 4 with adverse clinical parameters. It could
represent: i) a surrogate marker of cancer-associated disruption
at FRA16D, ii) a surrogate marker of cancer-associated
disruption of splicing fidelity, iii) an oncogenic, gain of function
WWOX isoform, or iv) a dominant negative WWOX iso-
form. WWOX variant 4 predicts a protein lacking the enzymatic
oxidoreductase function, but retaining the protein binding
WW-domains, and thus suggests possible function as a
dominant negative isoform, sequestering binding partners of
WWOX isoform 1 and inhibiting its putative tumour suppressor
role. In this regard, it is important to note that WWOX iso-
form 1 and WWOX isoform 4 have different intracellular
locations. While WWOX isoform 4 is located in the nucleus,
WWOX isoform 1 is located normally in the cytoplasm, but
translocates to the nucleus following TNF-
 
· treatment (14,15).
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This suggests that low levels of WWOX isoform 4 do not
preclude it having a dominant negative effect on the function
of WWOX isoform 1, as competition for binding partners may
not be on an equal basis.
However, it is also known that alternative splicing variants
are commonly associated with cancer. It has been estimated
that in normal cells spliceosome errors occur in 2-3% of trans-
cripts (23), and this rises to 10-20% of transcripts in cancer
cells (24). Cancer-associated splice variants have been reported
for a number of genes including EGFR, CD44 and NER (25).
Some of these alternate transcripts have the potential to play
a role in tumourigenesis e.g., by inhibiting apoptosis (CD79)
(26) or by blocking tumour suppressor activity (BIN 1) (27).
Wang et al (28) performed a genome-wide computational
screen identifying 26,258 alternative splicing variants, of
which 845 were significantly associated with human cancer.
It thus seems that cancer is associated with a generalised
relaxation of splicing fidelity, perhaps due to mutation or
altered expression of components of the splicing apparatus. Our
results here reveal low levels of WWOX variant 4 expression
in 69% of non-malignant ovarian tissues, a frequency similar
to that detected in ovarian tumours. Alternate WWOX trans-
cripts have been noted in normal tissues previously but this
has been somewhat understated (20,21). This perhaps argues
against a dominant negative hypothesis, and suggests that the
variant may be an infrequently produced splice form, even in
normal cells.
The role of WWOX variant 4 is clearly speculative at this
time and progress is reliant on the demonstration that it is
actually translated. In addition, the possible dominant negative
role of variant 4 could be tested using the following models:
i) transfection of variant 4 into immortalised human ovarian
surface epithelial cells that express normal WWOX variant 1,
or ii) RNAi knockdown of variant 4 expression in cell lines that
are abundant expressers of both WWOX variant 1 and variant 4.
These models can then be used to determine whether regulation
of variant 4 expression can i) abrogate, or ii) reconstitute
WWOX-mediated suppression of tumourigenicity in nude
mice.
In summary, we show that the expression of full-length
WWOX (variant 1) is significantly and frequently reduced in
ovarian tumours compared to normal ovarian tissue. This
decreased variant 1 expression is not associated with any
particular clinicopathological factor, but is decreased across
all the tumour subtypes, suggesting that reduced WWOX
variant 1 expression is a frequent and early event in ovarian
tumourigenesis. We also demonstrate that the predominant
WWOX alternate transcript (variant 4) is significantly associated
with advanced ovarian cancer. We report the first evidence
that this variant splice form is frequently expressed in non-
malignant ovarian tissue, arguing against its involvement in
tumourigenesis. These findings taken together strengthen
the case for the WWOX gene and full length expression as
demonstrating a tumour suppressor role.
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